Rifaximin, Oral Antibiotic, Named Orphan Drug for Potential to Ease Pain Crises
The U.S. Food and Drug Administration (FDA) has designated rifaximin, an oral antibiotic, an orphan drug as a potential treatment of pain crises due to sickle cell disease (SCD), according to a press release. A Phase 2 trial testing this antibiotic in SCD patients, in a new formulation for…